Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature

Clin Rheumatol. 2012 Aug;31(8):1259-61. doi: 10.1007/s10067-012-2002-8. Epub 2012 May 27.

Abstract

Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adalimumab
  • Adult
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived / administration & dosage*
  • Antirheumatic Agents / administration & dosage*
  • Demyelinating Diseases / chemically induced*
  • Demyelinating Diseases / drug therapy
  • Etanercept
  • Female
  • Humans
  • Immunoglobulin G / administration & dosage
  • Infliximab
  • Magnetic Resonance Imaging
  • Receptors, Tumor Necrosis Factor / administration & dosage
  • Rituximab
  • Severity of Illness Index
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / physiopathology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Tumor Necrosis Factor-alpha
  • Rituximab
  • Infliximab
  • Adalimumab
  • Etanercept